Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise - Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise - Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on Wednesday released topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity. Hypothalamic obesity is a rare type of obesity resulting from damage to the hypothalamus, a brain region that regulates appetite and metabolism. Bivamelagon achieved statistically significan…

Rhythm’s stock climbs on encouraging Phase II obesity drug data

Rhythm Pharaceuticals will speak with the FDA and EMA about advancing its obesity drug to Phase III trials.The post Rhythm’s stock climbs on encouraging Phase II obesity drug data appeared first on Clinical Trials Arena.

Rhythm says oral rare obesity drug clears Phase 2 test, plans tweaks to formulation

Rhythm Pharmaceuticals said Wednesday its oral candidate for a rare form of obesity produced “statistically significant and clinically meaningful” reductions in BMI in a mid-stage trial. The biotech also said that it is fine-tuning the ...